Extended Data Fig. 1: Cohort selection in the implementation stage of SHIELD.

In the implementation stage, 30,109 pregnant women were enrolled. Furthermore, 8,465 underwent follow-up, and 21,644 pregnant women were included in study population. Finally, PVST was completed for 16,908 participants. PVST, postvaccination serological testing.